Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quattro ICD lead approved in Japan

This article was originally published in The Gray Sheet

Executive Summary

Medtronic receives approval Dec. 10 to market its Sprint Quattro defibrillator lead in Japan. The approval puts a Medtronic lead back on the Japanese market, following the recall of the firm's newer Sprint Fidelis lead on Oct. 15 that raised concerns about repercussions in that country (1"The Gray Sheet" Oct. 22, 2007, p. 3). Quattro, used in implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices, has been available in the United States and Europe since 2001. Quattro will launch in Japan as soon as it receives reimbursement. Wachovia analyst Larry Biegelsen said the approval will add $35 million-$40 million to Medtronic's ICD sales estimates in the first half of 2008, taking Japanese share from competitors Boston Scientific and St. Jude Medical
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT025636

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel